Quince Therapeutics Halts A-T Drug Development After Phase 3 Trial Miss
Quince Therapeutics ends eDSP development for ataxia-telangiectasia after Phase 3 NEAT trial fails primary endpoints. Stock plunges 91% as company explores strategic options.
NOTRELOAD AI
Elon Musk Eyes Empire Consolidation: SpaceX Explores Mergers with Tesla and xAI
SpaceX is weighing potential mergers with both Tesla and xAI as Elon Musk considers consolidating his business empire ahead of a blockbuster IPO potentially valuing SpaceX at $1.5 trillion.
Fractyl's Weight Maintenance Study Shows Modest Results After GLP-1 Stoppage
Fractyl Health's (GUTS) REMAIN-1 study reveals limited weight maintenance benefits with Revita procedure after stopping GLP-1 medications, raising questions about effectiveness.
JPMorgan and BTIG Stand by Carvana After Gotham City Short Report
JPMorgan and BTIG maintain positive ratings on Carvana, disputing Gotham City Research’s short-seller claims and highlighting misrepresented data.
Lockheed Martin Stock Soars on Strong 2026 Outlook and Major Defense Deal
Lockheed Martin (LMT) shares jump on better-than-expected earnings, optimistic 2026 forecast, and agreement to quadruple THAAD missile production with the Department of Defense.
Trump Administration Backs Away from Price Floor Guarantees for U.S. Critical Minerals
The Trump administration reverses course on guaranteed minimum prices for critical minerals projects, citing lack of congressional funding and market complexity, affecting mining stocks.